Pillar 1 - FTO (new thread), page-403

Sn — you need to keep reading .

This is the entire point ,written about in here this week alon—that there are no real competitors to bisantrene.

Bisantrene was better than a country mile compared to nos 2 through 6 etc in the clinical study .
Much better , remarkably so to coin Dr Cullity (RAC Chairman) favourite word . And brequinar , the no 2 compound , was trialed in the past for organ replacement therapy —apart from dangerous immune-suppression actions which makes it unsuited as a cancer treatment drug , it does not have consistent drug dosing regime ability across patients, with wildly varying drug dosages for effects between individual patients and for when negative reactions occur . In short = not good . Known significant problems with the no. 2 FTO inhibitor agent in the COH study , which performed significantly lower than bisantrene anyway.

Other drug compounds — *have not been trialed in people , not even to phase 1 **. So safety unknown, and dose profiles etc are not known , let alone therapeutic effects !

Bisantrene has known safety , and dose regimes are known and understood.

Bisantrene has been through over 40 clinical trials , inc last years Sheba trial ; and most importantly has proven efficacy and effectiveness even in highly refractory cases ..and very advanced cancers(relapsed , not responsive to existing treatments inc anthracyclines resistance ) - which we now realise , that these cancers have associations with FTO protein over -expression